Table 2 Subgroup analyses for respiratory tract infection.
Treatment | No. of studies | With PAH-specific therapy | With placebo therapy | Total | RR | 95%CI (p value) | Homogeneity | |
|---|---|---|---|---|---|---|---|---|
I 2 (%) | p value | |||||||
Class of PAH-specific drugs | ||||||||
Prostanoids | 6 | 49/651(7.5%) | 58/579(10.0%) | 107/1230(8.7%) | 0.78 | 0.54–1.13(0.19) | 0.8 | 0.41 |
ERAs | 5 | 207/715(29.0%) | 119/465(25.6%) | 326/1180(27.6%) | 1.14 | 0.93–1.40(0.20) | 59.5 | 0.04 |
PDE5 inhibitors | ||||||||
PACES25 | 1 | 89/134(66.4%) | 72/131(55.0%) | 161/265(60.8%) | 1.21 | 0.99–1.47(0.06) | — | — |
PHIRST6 | 1 | 30/323(9.3%) | 3/82(3.7%) | 33/405(8.1%) | 2.54 | 0.79–8.11(0.12) | — | — |
PHIRST-1b13 | 1 | 6/74(8.1%) | 2/37(5.4%) | 8/111(7.2%) | 1.50 | 0.32–7.07(0.61) | — | — |
sGCs | 3 | 49/502(9.8%) | 20/220(9.1%) | 69/722(9.6%) | 1.06 | 0.65–1.73(0.80) | 0 | 0.68 |
Selective prostacyclin receptor agonist | 1 | 146/575(25.4%) | 168/577(29.1%) | 314/1152(27.3%) | 0.87 | 0.72–1.05(0.16) | — | — |
Monotherapy or combination therapy | ||||||||
Monotherapy vs. Placebo | 4 | 33/366(0%) | 21/196(1.5%) | 1/129(0.8%) | 0.86 | 0.51–1.44(0.57) | 12.2 | 0.33 |
combination therapy vs. Monotherapy | 15 | 605/2911(0%) | 571/2499(2.3%) | 3/262(1.1%) | 0.99 | 0.90–1.10(0.91) | 41.0 | 0.04 |
